Key facts
- Notable investors include Changchun Huize Investment.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Runuo Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Runuo Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Runuo Biotechnology
Manufacturer of biotechnology reagents designed to deliver accurate detection of parasitic and infectious agents for clinical and research applications. The company offers CRISPR-based diagnostic kits and dual-enzyme inorganic nanoflower ELISA reagents, enabling healthcare providers and laboratories to achieve rapid, sensitive, and dependable pathogen identification.
- Sector
- Healthcare
- HQ
- Changchun, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Runuo Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Runuo Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Runuo Biotechnology in its N-PORT filings yet. We sweep new filings monthly.